Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | TSHR | P16473 | 3/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | ACLY | P53396 | 1/20 | 0.32 |
| ▸ | ACACB | O00763 | 1/20 | 0.31 |
| ▸ | ACACA | Q13085 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18302657 | 1.00 | ALDH1A1 (0.37) | ALDH1A1TSHRMAPK1ACLYACACB | |
| SCHEMBL5249504 | 0.80 | TET2 (0.38) | ALDH1A1TSHRMAPK1CYP2D6CYP2C19 | |
| SCHEMBL901032 | 0.78 | ACLY (0.38) | ALDH1A1TSHRMAPK1ACLYACACB | |
| SCHEMBL3193100 | 0.78 | ALDH1A1 (0.34) | ALDH1A1TSHRMAPK1HIF1ATP53 | |
| SCHEMBL29925677 | 0.77 | ACLY (0.32) | ALDH1A1TSHRACLYACACBACACA | |
| SCHEMBL18312534 | 0.77 | ALDH1A1 (0.38) | ALDH1A1TSHRMAPK1TP53CYP3A4 | |
| SCHEMBL20695620 | 0.77 | ALDH1A1 (0.38) | ALDH1A1TSHRMAPK1TP53CYP3A4 | |
| SCHEMBL2996873 | 0.77 | TSHR (0.37) | ALDH1A1TSHRMAPK1CYP2D6CYP2C19 | |
| SCHEMBL14836310 | 0.76 | ALDH1A1 (0.32) | ALDH1A1TP53CYP3A4 | |
| Ammonia Solution, Strong SCHEMBL11297294 | 0.75 | ALDH1A1 (0.36) | ALDH1A1TSHRMAPK1TP53CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5922633-A | THERMAL LATENT ACID CATALYST CONSISTS OF AN EPOXY COMPOUND, A SULFUR COMPOUND AND LEWIS ACID | NOF CORPORATION (JP) | 1999-07-13 | — | — | US | claimed |
| CN-111635373-B | Polycyclic sulfonamide ROR gamma modulators | 山东轩竹医药科技有限公司 | 2022-07-12 | — | — | CN | disclosed |
| EP-3307738-B1 | ARYL DIHYDRO-2H-BENZO[B][1,4]OXAZINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORY AND THE TREATMENT OF DISEASE | UNIV MICHIGAN REGENTS (US) | 2022-04-20 | — | — | EP | disclosed |
| CN-107980042-B | Aryldihydro-2H-benzo [ b ] [1,4] oxazine sulfonamides and related compounds as ROR gamma agonists and for the treatment of disease | 莱斯拉公司 | 2021-10-08 | — | — | CN | disclosed |
| US-11059796-B2 | Aryl dihydro-2H benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2021-07-13 | — | — | US | disclosed |
| US-20210061778-A1 | ARYL DIHYDRO-2H BENZO[B][1,4]OXAZINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORY AND THE TREATMENT OF DISEASE | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2021-03-04 | — | — | US | disclosed |
| CN-111635373-A | Polycyclic sulfonamide ROR gamma modulators | 山东轩竹医药科技有限公司 | 2020-09-08 | — | — | CN | disclosed |
| US-20200261463-A1 | TREATMENT OF CANCER USING ARYL DIHYDRO-2H-BENZO[B][1,4]OXAZINE SULFONAMIDE COMPOUNDS | LYCERA CORPORATION | 2020-08-20 | — | — | US | disclosed |
| CN-111499591-A | ROR gamma modulators | 山东轩竹医药科技有限公司 | 2020-08-07 | — | — | CN | disclosed |
| US-10611740-B2 | Aryl dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease | LYCERA CORPORATION (US) | 2020-04-07 | — | — | US | disclosed |
| US-6103387-A | THERMOSETTING RESIN COMPRISING A CERAMIC, WHICH GIVES A CURED PRODUCT HAVING EXCELLENT STAIN RESISTANCE, STAIN-REMOVING PROPERTY, WEATHERING RESISTANCE, LIGHT RESISTANCE, CHEMICAL RESISTANCE, MOISTURE RESISTANCE AND APPEARANCE | NOF CORPORATION (JP) | 2000-08-15 | — | — | US | disclosed |
| US-6030571-A | Methods of molding and molded articles made thereby | NOF CORPORATION (JP) | 2000-02-29 | — | — | US | disclosed |
| US-5993909-A | COMPRISING EPOXY GROUP CONTAINING MODIFIED POLYESTER AND A COMPOUND CONTAINING FUNCTIONAL GROUPS PER MOLECULE; COATINGS, INKS, ADHESIVES | NOF CORPORATION (JP) | 1999-11-30 | — | — | US | disclosed |
| US-5922633-A | THERMAL LATENT ACID CATALYST CONSISTS OF AN EPOXY COMPOUND, A SULFUR COMPOUND AND LEWIS ACID | NOF CORPORATION (JP) | 1999-07-13 | — | — | US | disclosed |
| EP-0805186-A1 | THERMOSETTING COMPOSITION, METHOD OF FINISH COATING, AND COATED ARTICLES | NOF CORPORATION (JP) | 1997-11-05 | — | — | EP | disclosed |
| US-5661219-A | AN ACRYLIC COPOLYMER HAVING CARBOXY GROUPS BLOCKED BY A VINYL ETHER, A REACTIVE POLYMER, E.G.HAVING EPOXY GROUPS, AND LEWIS ACID-COMPLEX CATALYST; HIGH SOLIDS; LOW TEMPERATURE CURING; STORAGE STABILITY; MECHANICAL PROPERTIES | NOF CORPORATION (JP) | 1997-08-26 | — | — | US | disclosed |
| EP-0643112-B1 | Curable composition, thermal latent acid catalyst, method of coating, coated article, method of molding and molded article | NOF CORP (JP) | 1997-07-30 | — | — | EP | disclosed |
| EP-0774476-A1 | THERMOSETTING COMPOSITION, METHOD OF FINISH COATING, AND COATED ARTICLES | NOF CORPORATION (JP) | 1997-05-21 | — | — | EP | disclosed |
| EP-0709415-A2 | Curable base-coat composition, method of film-forming and coated articles | NOF CORPORATION (JP) | 1996-05-01 | — | — | EP | disclosed |
| EP-0643112-A2 | Curable composition, thermal latent acid catalyst, method of coating, coated article, method of molding and molded article | NOF CORPORATION (JP) | 1995-03-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11059796-B2 | Aryl dihydro-2H benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease | RORB, RORA, RORC | ALDH1A1 170/4885TSHR 1119/4885MAPK1 3302/4885 |
| US-10611740-B2 | Aryl dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease | RORB, RORA, RORC | ALDH1A1 172/4885TSHR 971/4885MAPK1 3269/4885 |
| US-20200261463-A1 | TREATMENT OF CANCER USING ARYL DIHYDRO-2H-BENZO[B][1,4]OXAZINE SULFONAMIDE COMPOUNDS | DPYD, IDH2, IDH1 | ALDH1A1 5/4885TSHR 3878/4885MAPK1 3664/4885 |
| US-20210061778-A1 | ARYL DIHYDRO-2H BENZO[B][1,4]OXAZINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORY AND THE TREATMENT OF DISEASE | RORB, RORA, RORC | ALDH1A1 151/4885TSHR 978/4885MAPK1 3150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.